Research Summary
Dapagliflozin-linagliptin combo improves glycemic control and organ protection
Moderate confidence
Low bias
Last updated June 19, 2026Key Takeaway:
This study evaluated the combination therapy of Dapagliflozin and Linagliptin in managing Type 2 Diabetes and hypertension, showing significant improvements in various health metrics.
Study at a Glance
What was studied
Dapagliflozin-linagliptin combination therapy in adults with type 2 diabetes and hypertension.
Participants
Middle Aged (40-64)
Male, Female
with T2 Diabetes
Intervention
Dapagliflozin
Outcomes
Time in range, HbA1c, Fasting Plasma Glucose (FPG), Systolic blood pressure, Triglycerides, ALT, Urinary albumin-to-creatinine ratio, Estimated glomerular filtration rate
Funding
Non-Industry Sponsored
Save this study and add notes to your research library.
Main Effects
Combination therapy achieved a time in range of 94.86%, significantly higher than ~80% in monotherapies (P<0.001).
HbA1c levels decreased to 5.52%, indicating improved glycemic control.
Systolic blood pressure reduced to 124 mmHg, demonstrating effective hypertension management.
Evidence Summary
| Intervention | Outcome | Measured Change | Study Effect |
|---|---|---|---|
 Dapagliflozin (Medications) |  Alanine Aminotransferase (ALT) (Metabolic Health) | Decrease | Strong |
Dapagliflozin (Medications) |  Estimated glomerular filtration rate (Clinical Outcomes) | Increase | Strong |
Dapagliflozin (Medications) |  Fasting Plasma Glucose (FPG) (Glycemic Control) | Decrease | Strong |
Dapagliflozin (Medications) | HbA1c (Glycemic Control) | Decrease | Strong |
Dapagliflozin (Medications) | Systolic blood pressure (Metabolic Health) | Decrease | Strong |
Dapagliflozin (Medications) | Time in range (Glycemic Control) | Increase | Strong |
Dapagliflozin (Medications) | Triglycerides (Metabolic Health) | Decrease | Strong |
Dapagliflozin (Medications) | Urinary albumin-to-creatinine ratio (Clinical Outcomes) | Decrease | Strong |
Unlock Full Evidence Analysis
Create a free account to access effectiveness ratings, evidence strength and depth scores, consistency analysis, and direct links to all supporting studies.
Evidence Suggest
- Time in range improved to 94.86% with combination therapy (P<0.001).
- HbA1c reduced by 3.31% to 5.52% (P<0.001).
- Systolic blood pressure decreased by 27.2 mmHg to 124 mmHg (P<0.001).
Who this applies to
- Adults diagnosed with Type 2 Diabetes.
- Patients also experiencing hypertension.
Keep in Mind
- The study's non-randomized design limits causal conclusions.
- Findings may not apply to younger populations or those with different comorbidities.
- Further research is needed to confirm long-term effects.
Between the Lines
- Non-randomized design may introduce bias.
- Results may not be generalizable to all populations.
- Limited long-term follow-up data.
Unlock Full Analysis
Create a free account to unlock the bias score, detailed effectiveness analysis, and clinical outcomes for this study.
Already have an account?
Journal Reference
WenXia L, RuRan L, ShanShan L, et al. Combination Therapy with Dapagliflozin and Linagliptin for Type 2 Diabetes and Hypertension. Frontiers in Endocrinology. 2026;17. doi:10.3389/fendo.2026.1802641
Connected Evidence
Discover how this study fits into the broader diabetes evidence landscape.
This study contributes to evidence on SGLT2 Inhibitors and Glycemic Control, SGLT2 Inhibitors and Alanine Aminotransferase (ALT).
Related evidence relationships
Explore in Evidence ArchiveThis study contributes to the evidence on the following intervention–outcome relationships.
Included in these evidence collections
Curated evidence collections and hubs this study is part of.
Glycemic Control Evidence Hub
All studies measuring Glycemic Control
4 studies
outcome_hubMeasures Glycemic Control as a key outcome.
SGLT2 Inhibitors Evidence Hub
All studies on SGLT2 Inhibitors
4 studies
intervention_hubContributes to SGLT2 Inhibitors evidence base.
Blood Pressure Evidence Hub
All studies measuring Blood Pressure
2 studies
outcome_hubMeasures Blood Pressure as a key outcome.
Alanine Aminotransferase (ALT) Evidence Hub
All studies measuring Alanine Aminotransferase (ALT)
1 studies
outcome_hubMeasures Alanine Aminotransferase (ALT) as a key outcome.
Recent Diabetes Research
Latest published studies
recency_collection
Published within the last 2 years.
Explore more in the evidence archive
Jump to pre-filtered views in the evidence archive.
All studies on Dapagliflozin and HbA1c
Intervention: DapagliflozinOutcome: HbA1c
4 results
All studies on Dapagliflozin and Alanine Aminotransferase (ALT)
Intervention: DapagliflozinOutcome: Alanine Aminotransferase (ALT)
1 results
All studies on Dapagliflozin
Intervention: Dapagliflozin
4 results
All studies measuring HbA1c
Outcome: HbA1c
4 results
All studies measuring Alanine Aminotransferase (ALT)
Outcome: Alanine Aminotransferase (ALT)
1 results
Questions this evidence helps answer
Key clinical and research questions this study contributes to.
Does dapagliflozin improve HbA1c?
Based on connected evidence for Dapagliflozin and HbA1c.
Does dapagliflozin affect Alanine Aminotransferase (ALT) in people with diabetes?
Exploring evidence on Dapagliflozin and Alanine Aminotransferase (ALT) outcomes.
What does the evidence say about dapagliflozin and Systolic blood pressure?
Review of studies examining Dapagliflozin and Systolic blood pressure.
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.